PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab

J D Jensen, A Knoop, A V Laenkholm, M Grauslund, M B Jensen, E Santoni-Rugiu, M Andersson, M Ewertz

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

This study was conducted to determine the frequency of PIK3CA mutations and human epidermal growth factor receptor-2 (HER2) phosphorylation status (pHER2-Tyr1221/1222) and if PIK3CA, phosphatase and tensin homolog (PTEN), or pHER2 has an impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.
OriginalsprogEngelsk
TidsskriftAnnals of Oncology
Vol/bind23
Udgave nummer8
Sider (fra-til)2034-42
Antal sider9
ISSN0923-7534
DOI
StatusUdgivet - 2012

    Fingerprint

Citationsformater